DOCSLIB.ORG

682.Full.Pdf

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
682.Full.Pdf Endogenous and nitrovasodilator-induced release of NO in the airways of end-stage cystic fibrosis patients To the Editors: blood pressure changes recorded, as described previously [8] and in the online supplementary material. A variety of isoforms of nitric oxide (NO) synthases are constitutively expressed in human airway and vascular Nearly undetectable levels of NO were found in CF patients endothelial cells continuously generating NO. NO plays an representing an output of 7.6¡6 ppb over 30 s. This is in important role in regulating lung function in health and contrast to patients presented for routine open heart surgery disease including modulation of pulmonary vascular resis- (91.4¡21 ppb over 30 s; fig. 1). Representative traces are tance, airway calibre and host defence. Production of NO and shown in figure 1A and C of the online supplementary its consumption by fluid-phase reactions can be detected and material. monitored in the exhaled air, providing an important window There was a significant increase in gas-phase NO above baseline to assess the dynamics of NO metabolism in health and levels by 250 mg GTN boluses in CF patients (36.7¡6ppb), inflammatory lung conditions, asthma in particular [1]. which was comparable to that seen in control patients with A series of milestone studies uncovered a relative deficiency of routine open heart surgery (48.7¡4 ppb; fig. 1). Representative pulmonary NO availability in cystic fibrosis (CF), a severe traces of GTN-induced exhaled NO are presented in figure 1B chronic inflammatory lung disease with studies generally and D of the online supplementary material. showing reduced exhaled NO [2, 3]. However, there remains These findings provide novel insights into the current debate controversy regarding the anatomical localisation and mechan- on NO exchange dynamics in adult CF. Despite the chronic isms of NO deficiency, and its relationship with CF disease inflammatory nature of the disease, exhaled NO has been progression. By using extended exhaled NO analysis at reported unchanged or low depending on severity of the different expiratory flow rates, indirect studies have attempted disease [2, 4–7]. Our study investigating exhaled NO in to distinguish NO production into bronchial and alveolar ventilated patients undergoing lung transplantation clearly compartments based on basic models [4–7]. However, the fate demonstrates a profound reduction in endogenous gas-phase of NO delivered directly to the alveoli has not been demon- NO in the isolated lower airways of patients with end-stage strated in these patients. We aimed to investigate these issues CF. This conclusion must take into consideration both by evaluating endogenous exhaled NO in end-stage CF in methodological issues regarding tidal measurements of intubated patients undergoing lung transplantation and the exhaled NO and the potential influence of high endogenous dynamism of exhaled NO production from pulmonary micro- carbon dioxide (CO ) on exhaled NO. However, the same vascular metabolism of intravenous nitroglycerin (GTN) [8]. 2 methodology was used for our control population and during Breath-to-breath tidal measurements of NO concentrations in the GTN experiments in the CF patients. Regarding CO2,we the lower airways were performed using a real-time, computer- have not seen major effects of varying endogenous CO2 controlled and integrated system (Logan Research Ltd 2000 and between 3–6% (unpublished observations) but the potential 3000 series, Rochester, UK), as described previously [8[ and in effects of even higher end tidal CO2 in the CF patients cannot detail in the online supplementary material. be excluded. Unpublished observations with end-stage pul- monary hypertension demonstrating better-preserved exhaled To investigate gas-phase NO concentrations in the lower NO also suggest that the reduced endogenous exhaled NO in airways of patients with end-stage CF, seven patients (mean CF may be unique, and is unlikely to be the result of end-stage age, 26 yrs; five males and two females) presented for lung lung disease per se. transplantation were studied after induction of general anaesthetic with endotracheal intubation and mechanical The exact mechanisms of relative NO deficiency in CF are not ventilation. CF patients were contrasted to patients undergoing known. Recent studies utilising extended NO exchange routine open heart surgery for coronary artery bypass grafting analysis resulted in contradictory findings showing no altera- (CABG; n54) exhibiting normal lung function as judged by tions, increased or decreased bronchial fluxes and/or alveolar preoperative respiratory function testing and evaluation of NO concentrations in CF children and adults [4–7]. The routine chest radiography (mean age 56 yrs). The studies were emerging consensus suggests that the main mechanism of approved by the hospital ethics committee and patients NO deficiency in adult CF may relate to increased bronchial provided written consent. inflammation and associated defective NO synthase expres- sion, activity and NO production or increased degradation of Baseline measurements to evaluate endogenous production produced NO [2, 3, 6, 9]. The latter may involve bacterial and release of NO to the gas phase were performed after mechanisms, catalytic and chemical consumption by fluid induction of anaesthetic, prior to excision of the lungs for phase reactions, and during passage through the highly transplant patients, and prior to cardiopulmonary bypass in viscous mucous layer [6, 9]. CABG patients. This was followed in haemodynamically- stable patients with administration of a 250-mg bolus of GTN Our study expands current understanding of alveolar NO into the central venous catheter with exhaled NO and arterial exchange mechanisms by investigating NO fluxes arising from 682 VOLUME 36 NUMBER 3 EUROPEAN RESPIRATORY JOURNAL a) 125 mucosal consumption hypothesis for the dysregulated NO pathways in CF. Furthermore, they also suggest that the CF airways may be therapeutically targeted for exposure by NO 100 -1 through pulmonary metabolism of nitrovasodilators. " " " 75 T. Varga*,#, T. Kovesi+, J. Gal and N. Marczin*,#, *Section of Anaesthetics, Pain Medicine and Intensive Care, 50 Dept of Surgery and Cancer, Faculty of Medicine, Imperial College London, London, #Royal Brompton and Harefield NHS Exhaled NO ppb·30 s Foundation Trust, Harefield Hospital, Harefield, Middlesex, 25 " UK, Dept of Anaesthesiology and Intensive Therapy, Faculty of Medicine, Semmelweis University, Budapest, and +Dept of 0 Anaesthesiology and Intensive Therapy, Faculty of Medicine, b) 9 Pecs University, Pecs, Hungary. 8 Correspondence: N. Marczin, Dept of Anaesthetics, Harefield 7 Hospital, Harefield, Middlesex, UK, UB9 6JH. E-mail: n.marczin@ 6 imperial.ac.uk 5 Statement of Interest: None declared 4 3 REFERENCES Peak exhaled NO ppb 2 1 Kharitonov SA, Barnes PJ. Exhaled biomarkers. Chest 2006; 130: 1 1541–1546. 2 Grasemann H, Michler E, Wallot M, et al. Decreased concentration 0 of exhaled nitric oxide (NO) in patients with cystic fibrosis. Pediatr Baseline GTN Pulmonol 1997; 24: 173–177. 3 Kelley TJ, Drumm ML. Inducible nitric oxide synthase expression FIGURE 1. a) Area under curve over 30 s and b) peak exhaled nitric oxide is reduced in cystic fibrosis murine and human airway epithelial (NO) of endogenous gas-phase NO (baseline NO) and exhaled NO in response to cells. J Clin Invest 1998; 102: 1200–1207. intravenous administration of 250-mg bolus of nitroglycerin (GTN) in control patients 4 Shin HW, Rose-Gottron CM, Sufi RS, et al. Flow-independent nitric presenting for open heart surgery for coronary arterial bypass grafting or for lung oxide exchange parameters in cystic fibrosis. Am J Respir Crit Care transplantation and for end-stage cystic fibrosis. GTN values represent changes Med 2002; 165: 349–357. over baseline. 5 Suri R, Paraskakis E, Bush A. Alveolar, but not bronchial nitric oxide production is elevated in cystic fibrosis. Pediatr Pulmonol pulmonary microvascular metabolism of exogenous nitrogly- 2007; 42: 1215–1221. cerin. Our in vivo studies in patients appear to confirm the ex 6 Hofer M, Mueller L, Rechsteiner T, et al. Extended nitric oxide vivo observations of HENNO et al. [10] regarding preserved measurements in exhaled air of cystic fibrosis and healthy adults. endothelium independent vasodilation by nitroprusside in Lung 2009; 187: 307–313. 7 isolated vascular rings of CF pulmonary arteries. Our Hubert D, Aubourg F, Fauroux B, et al. Exhaled nitric oxide in cystic fibrosis: relationships with airway and lung vascular preliminary results extend these studies to the microvascula- impairments. Eur Respir J 2009; 34: 117–124. ture and airway compartments by suggesting a notably 8 Marczin N, Riedel B, Royston D, et al. Intravenous nitrate preserved ability of the end-stage CF lung microvasculature vasodilators and exhaled nitric oxide. Lancet 1997; 349: 1742. to convert GTN and release NO into the alveoli and airways 9 Grasemann H, Lax H, Treseler JW, et al. Dornase alpha and without evidence of increased consumption either in the exhaled NO in cystic fibrosis. Pediatr Pulmonol 2004; 38: 379–385. alveolar fluid or gas phase. This is remarkable in relation to 10 Henno P, Maurey C, Danel C, et al. Pulmonary vascular both the profound reduction in endogenous NO release and dysfunction in end-stage cystic fibrosis: role of NF-kB and the potential for pulmonary vascular dysfunction associated endothelin-1. Eur Respir J 2009; 34: 1329–1337. with end-stage CF in some patients [7, 10]. Altogether, these data lend strong support for the bronchial epithelial and DOI: 10.1183/09031936.00025610 c EUROPEAN RESPIRATORY JOURNAL VOLUME 36 NUMBER 3 683.
Load more

Recommended publications
  • Tolerance and Resistance to Organic Nitrates in Human Blood Vessels
    \ö-\2- Tolerance and Resistance to Organic Nitrates in Human Blood Vessels Peter Radford Sage MBBS, FRACP Thesis submit.ted for the degree of Doctor of Philosuphy Department of Medicine University of Adelaide and Cardiology Unit The Queen Elizabeth Hospital I Table of Gontents Summary vii Declaration x Acknowledgments xi Abbreviations xil Publications xtil. l.INTRODUCTION l.L Historical Perspective I i.2 Chemical Structure and Available Preparations I 1.3 Cellular/biochemical mechanism of action 2 1.3.1 What is the pharmacologically active moiety? 3 1.3.2 How i.s the active moiety formed? i 4 1.3.3 Which enzyme system(s) is involved in nitrate bioconversi<¡n? 5 1.3.4 What is the role of sulphydryl groups in nitrate action? 9 1.3.5 Cellular mechanism of action after release of the active moiety 11 1.4 Pharmacokinetics t2 1.5 Pharmacological Effects r5 1.5.1 Vascular effects 15 l.5.2Platelet Effects t7 1.5.3 Myocardial effects 18 1.6 Clinical Efhcacy 18 1.6.1 Stable angina pectoris 18 1.6.2 Unstable angina pectoris 2t 1.6.3 Acute myocardial infarction 2l 1.6.4 Congestive Heart Failure 23 ll 1.6.5 Other 24 1.7 Relationship with the endothelium and EDRF 24 1.7.1 EDRF and the endothelium 24 1.7.2 Nitrate-endothelium interactions 2l 1.8 Factors limiting nitrate efficacy' Nitrate tolerance 28 1.8.1 Historical notes 28 1.8.2 Clinical evidence for nitrate tolerance 29 1.8.3 True/cellular nitrate tolerance 31 1.8.3.1 Previous studies 31 | .8.3.2 Postulated mechanisms of true/cellular tolerance JJ 1.8.3.2.1 The "sulphydryl depletion" hypothesis JJ 1.8.3.2.2 Desensitization of guanylate cyclase 35 1 8.i.?..3 Impaired nitrate bioconversion 36 1.8.3.2.4'Ihe "superoxide hypothesis" 38 I.8.3.2.5 Other possible mechanisms 42 1.8.4 Pseudotolerance ; 42 1.8.4.
    [Show full text]
  • A Textbook of Clinical Pharmacology and Therapeutics This Page Intentionally Left Blank a Textbook of Clinical Pharmacology and Therapeutics
    A Textbook of Clinical Pharmacology and Therapeutics This page intentionally left blank A Textbook of Clinical Pharmacology and Therapeutics FIFTH EDITION JAMES M RITTER MA DPHIL FRCP FMedSci FBPHARMACOLS Professor of Clinical Pharmacology at King’s College London School of Medicine, Guy’s, King’s and St Thomas’ Hospitals, London, UK LIONEL D LEWIS MA MB BCH MD FRCP Professor of Medicine, Pharmacology and Toxicology at Dartmouth Medical School and the Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, USA TIMOTHY GK MANT BSC FFPM FRCP Senior Medical Advisor, Quintiles, Guy's Drug Research Unit, and Visiting Professor at King’s College London School of Medicine, Guy’s, King’s and St Thomas’ Hospitals, London, UK ALBERT FERRO PHD FRCP FBPHARMACOLS Reader in Clinical Pharmacology and Honorary Consultant Physician at King’s College London School of Medicine, Guy’s, King’s and St Thomas’ Hospitals, London, UK PART OF HACHETTE LIVRE UK First published in Great Britain in 1981 Second edition 1986 Third edition 1995 Fourth edition 1999 This fifth edition published in Great Britain in 2008 by Hodder Arnold, an imprint of Hodden Education, part of Hachette Livre UK, 338 Euston Road, London NW1 3BH http://www.hoddereducation.com ©2008 James M Ritter, Lionel D Lewis, Timothy GK Mant and Albert Ferro All rights reserved. Apart from any use permitted under UK copyright law, this publication may only be reproduced, stored or transmitted, in any form, or by any means with prior permission in writing of the publishers or in the case of reprographic production in accordance with the terms of licences issued by the Copyright Licensing Agency.
    [Show full text]
  • Your Pulse and Target Heart Rate
    Skip to main content ×Close Menu We use cookies to improve your experience on our website. By closing this banner or interacting with our site, you acknowledge and agree to this. Legal Notices MobileClose Menu Find A Doctor Your Visit Pay a Bill Log in to MyGillette Learn more about MyGillette Patient Education Patient Services and Resources Your Rights and Medical Records Understanding Costs, Insurance and the Gillette Assistance Programs Services to Support Your Family Interpreter Services International Patients Parent Resources and Support Prepare for Your Visit Prepare for Clinic Visits and Tests Prepare for Surgery Take a Hospital Tour Transfer Your Medical Records Transportation and Accommodations Ways to Prepare and Comfort Your Child During Your Visit or Hospital Stay Commitment to a Safe and Healing Environment Our Hospital Units Your Hospital Room St. Paul Campus Amenities and Activities Visit or Contact a Patient Conditions & Care All Conditions Cerebral Palsy Neuromuscular Disorders Scoliosis Craniosynostosis Brain Injury All Tests & Treatments Shunt Surgery for Hydrocephalus Gait and Motion Analysis Selective Dorsal Rhizotomy (SDR) Gillette Craniocap© Orthosis Botulinum Toxin and Phenol (Injected Spasticity Medications) All Specialties & Services Orthopedics Rehabilitation Services Craniofacial and Plastic Surgery Neurology Neurosurgery Virtual Visits Pediatric Expert Consults Virtual Rehab Therapy Sleep Medicine Virtual Care Get Involved Advocating for Your Family Community Health United Cerebral Palsy of MN Donors & Supporters
    [Show full text]
  • Nitric Oxide, the Biological Mediator of the Decade: Fact Or Fiction?
    Eur Respir J 1997; 10: 699–707 Copyright ERS Journals Ltd 1997 DOI: 10.1183/09031936.97.10030699 European Respiratory Journal Printed in UK - all rights reserved ISSN 0903 - 1936 SERIES 'CLINICAL PHYSIOLOGY IN RESPIRATORY INTENSIVE CARE' Edited by A. Rossi and C. Roussos Number 14 in this Series Nitric oxide, the biological mediator of the decade: fact or fiction? S. Singh, T.W. Evans Nitric oxide, the biological mediator of the decade: fact or fiction? S. Singh, T.W. Evans. Unit of Critical Care, National Heart & ERS Journals Ltd 1997. Lung Institute, Royal Brompton Hospital, ABSTRACT: Nitric oxide (NO), an atmospheric gas and free radical, is also an London, UK. important biological mediator in animals and humans. Its enzymatic synthesis by constitutive (c) and inducible (i) isoforms of NO synthase (NOS) and its reactions Correspondence: T.W. Evans with other biological molecules such as reactive oxygen species are well charac- Royal Brompton Hospital Sydney Street terized. NO modulates pulmonary and systemic vascular tone through its vasodila- London SW3 6NP tor property. It has antithrombotic functions and mediates some consequences of UK the innate and acute inflammatory responses; cytokines and bacterial toxins induce widespread expression of iNOS associated with microvascular and haemodynam- Keywords: Acute respiratory distress syn- ic changes in sepsis. drome Within the lungs, a diminution of NO production is implicated in pathological hypoxic pulmonary vasoconstriction states associated with pulmonary hypertension, such as acute respiratory distress nitric oxide syndrome: inhaled NO is a selective pulmonary vasodilator and can improve ven- nitric oxide synthase tilation-perfusion mismatch. However, it may have deleterious effects through mod- pulmonary hypertension ulating hypoxic pulmonary vasoconstriction.
    [Show full text]
  • The Heart Institute
    The Heart Institute Division of Cardiology 4650 Sunset Blvd., #34, Los Angeles, CA 90027 Phone: 323-361-2461 Fax: 323-361-1513 The Heart Institute at Children’s Hospital Los Angeles is CHLA.org/CARDIOLOGY one of the top-ranked pediatric heart programs in the Division of nation—with a long history of exceptional and innovative Cardiothoracic Surgery 4650 Sunset Blvd., #66 care for the most complex pediatric cardiac conditions. Los Angeles, CA 90027 Phone: 323-361-4148 Fax: 323-361-3668 We treat patients from fetus to adulthood and serve as CHLA.org/CTSurgery a major tertiary referral center for all forms of congenital Referrals Phone: 888-631-2452 and acquired heart disease. Fax: 323-361-8988 Email: [email protected] Physician Portal: https://myCHLA.CHLA.org We offer an integrated inpatient and outpatient Our Cardiothoracic Intensive Care Unit (CTICU) complement of services that brings together experts was the first of its kind on the West Coast, using in cardiology, cardiothoracic surgery, cardiothoracic innovative treatments including extracorporeal transplant, cardiothoracic intensive care and membrane oxygenation (ECMO) and ventricular cardiovascular acute care in a centrally located, assist services. state-of-the-art healing environment. With fewer steps to navigate, our patients and families receive care Our two state-of-the-art catheterization laboratories that is more streamlined and less stressful. use the latest technology to provide accurate cardiac data while reducing radiation. Our programmatic emphasis on high-complexity surgeries in neonates has produced outcomes that are among the best in the country, as shown in the most recent Society of Thoracic Surgeons report.
    [Show full text]
  • Current Advances of Nitric Oxide in Cancer and Anticancer Therapeutics
    Review Current Advances of Nitric Oxide in Cancer and Anticancer Therapeutics Joel Mintz 1,†, Anastasia Vedenko 2,†, Omar Rosete 3 , Khushi Shah 4, Gabriella Goldstein 5 , Joshua M. Hare 2,6,7 , Ranjith Ramasamy 3,6,* and Himanshu Arora 2,3,6,* 1 Dr. Kiran C. Patel College of Allopathic Medicine, Nova Southeastern University, Davie, FL 33328, USA; [email protected] 2 John P Hussman Institute for Human Genomics, Miller School of Medicine, University of Miami, Miami, FL 33136, USA; [email protected] (A.V.); [email protected] (J.M.H.) 3 Department of Urology, Miller School of Medicine, University of Miami, Miami, FL 33136, USA; [email protected] 4 College of Arts and Sciences, University of Miami, Miami, FL 33146, USA; [email protected] 5 College of Health Professions and Sciences, University of Central Florida, Orlando, FL 32816, USA; [email protected] 6 The Interdisciplinary Stem Cell Institute, Miller School of Medicine, University of Miami, Miami, FL 33136, USA 7 Department of Medicine, Cardiology Division, Miller School of Medicine, University of Miami, Miami, FL 33136, USA * Correspondence: [email protected] (R.R.); [email protected] (H.A.) † These authors contributed equally to this work. Abstract: Nitric oxide (NO) is a short-lived, ubiquitous signaling molecule that affects numerous critical functions in the body. There are markedly conflicting findings in the literature regarding the bimodal effects of NO in carcinogenesis and tumor progression, which has important consequences for treatment. Several preclinical and clinical studies have suggested that both pro- and antitumori- Citation: Mintz, J.; Vedenko, A.; genic effects of NO depend on multiple aspects, including, but not limited to, tissue of generation, the Rosete, O.; Shah, K.; Goldstein, G.; level of production, the oxidative/reductive (redox) environment in which this radical is generated, Hare, J.M; Ramasamy, R.; Arora, H.
    [Show full text]
  • Medical Management of Advanced Heart Failure
    CLINICAL CARDIOLOGY CLINICIAN’S CORNER Medical Management of Advanced Heart Failure Anju Nohria, MD Context Advanced heart failure, defined as persistence of limiting symptoms de- Eldrin Lewis, MD spite therapy with agents of proven efficacy, accounts for the majority of morbidity and mortality in heart failure. Lynne Warner Stevenson, MD Objective To review current medical therapy for advanced heart failure. EART FAILURE HAS EMERGED AS Data Sources We searched MEDLINE for all articles containing the term advanced a major health challenge, in- heart failure that were published between 1980 and 2001; EMBASE was searched from creasing in prevalence as age- 1987-1999, Best Evidence from 1991-1998, and Evidence-Based Medicine from 1995- adjusted rates of myocardial 1999. The Cochrane Library also was searched for critical reviews and meta-analyses Hinfarction and stroke decline.1 Affect- of congestive heart failure. ing 4 to 5 million people in the United Study Selection Randomized controlled trials of therapy for 150 patients or more States with more than 2 million hospi- were included if advanced heart failure was represented. Other common clinical situ- talizations each year, heart failure alone ations were addressed from smaller trials as available, trials of milder heart failure, con- accounts for 2% to 3% of the national sensus guidelines, and both published and personal clinical experience. health care budget. Developments her- Data Extraction Data quality was determined by publication in peer-reviewed lit- alded in the news media increase pub- erature or inclusion in professional society guidelines. lic expectations but focus on decreas- Data Synthesis A primary focus for care of advanced heart failure is ongoing iden- ing disease progression in mild to tification and treatment of the elevated filling pressures that cause disabling symp- moderate stages2,3 or supporting the cir- toms.
    [Show full text]
  • The Evolution of Heart Failure with Reduced Ejection Fraction Pharmacotherapy: What Do We Have and Where Are We Going?
    Pharmacology & Therapeutics 178 (2017) 67–82 Contents lists available at ScienceDirect Pharmacology & Therapeutics journal homepage: www.elsevier.com/locate/pharmthera Associate editor: M. Curtis The evolution of heart failure with reduced ejection fraction pharmacotherapy: What do we have and where are we going? Ahmed Selim, Ronald Zolty, Yiannis S. Chatzizisis ⁎ Division of Cardiovascular Medicine, University of Nebraska Medical Center, Omaha, NE, USA article info abstract Available online 21 March 2017 Cardiovascular diseases represent a leading cause of mortality and increased healthcare expenditure worldwide. Heart failure, which simply describes an inability of the heart to meet the body's needs, is the end point for many Keywords: other cardiovascular conditions. The last three decades have witnessed significant efforts aiming at the discovery Heart failure of treatments to improve the survival and quality of life of patients with heart failure; many were successful, Reduced ejection fraction while others failed. Given that most of the successes in treating heart failure were achieved in patients with re- Pharmacotherapy duced left ventricular ejection fraction (HFrEF), we constructed this review to look at the recent evolution of Novel drugs HFrEF pharmacotherapy. We also explore some of the ongoing clinical trials for new drugs, and investigate poten- tial treatment targets and pathways that might play a role in treating HFrEF in the future. © 2017 Elsevier Inc. All rights reserved. Contents 1. Introduction..............................................
    [Show full text]
  • Heart Failure
    FACT SHEET FOR PATIENTS AND FAMILIES Heart Failure What is it? Enlarged heart Heart failure is a condition in which your heart can’t pump enough blood to meet your body’s needs. Usually, this is because your heart muscle is too weak to “squeeze” out enough blood with each beat. But heart failure can also happen when your heart gets stiff “Normal” heart and can’t fill up with enough blood between each beat. Heart failure is found most often in older people, but it can happen to anyone at any age. It’s a serious condition — and also quite common. Many people with heart failure continue to have a full and active life for many years after their diagnosis. What are the symptoms? Symptoms of heart failure vary based on the type of With heart failure, initial damage weakens the heart failure you have. Common symptoms include: heart muscle. This makes your heart beat faster, and the muscle stretches or thickens. Over time, • Shortness of breath the heart muscle begins to wear out. • Cough • Feeling very tired and weak • Atherosclerosis (coronary artery disease). • Weight gain (from fluid buildup) Atherosclerosis is when the arteries that supply your • Swollen ankles, feet, belly, lower back, and fingers heart with blood become narrowed by fatty plaque • Puffiness or swelling around the eyes buildup. This restricts the amount of oxygen your • Trouble concentrating or remembering heart gets and weakens the muscle. It can also cause a heart attack, which can damage your heart even more. The main cause of heart failure (heart muscle damage and weakness) cannot be cured, but symptoms can be • High blood pressure (hypertension).
    [Show full text]
  • Investigations Into the Role of Nitric Oxide in Disease
    INVESTIGATIONS INTO THE ROLE OF NITRIC OXIDE IN CARDIOVASCULAR DEVXLOPMENT DISEASE: INSIGHTS GAINED FROM GENETICALLY ENGINEERED MOUSE MODELS OF HUMAN DISEASE Tony Lee A thesis submitted in conformity with the requirements for the degree of Master's of Science Institute of Medicai Science University of Toronto @ Copyright by Tony C. Lee (2000) National Library Bibliothèque nationale I*I of Canada du Canada Acquisitions and Acquisitions et Bibliogaphic Services services bibliogaphiques 395 Wellington Street 395, rue Wellington Ottawa ON K1A ON4 Ottawa ON KIA ON4 Canada Canada The author has granted a non- L'auteur a accordé une licence non exclusive licence allowing the exclusive permettant à la National Library of Canada to Bibliothèque nationale du Canada de reproduce, loan, distribute or sell reproduire, prêter, distribuer ou copies of this thesis in microfonn, vendre des copies de cette thèse sous paper or electronic formats. la forme de microfiche/nlm, de reproduction sur papier ou sur format électronique. The author retains ownership of the L'auteur conserve la propriété du copyright in this thesis. Neither the droit d'auteur qui protège cette thèse. thesis nor substantial extracts fkom it Ni la thèse ni des extraits substantiels may be printed or othewise de celle-ci ne doivent être imprimés reproduced without the author's ou autrement reproduits sans son permission. autorisation. INVESTIGATIONS INTO THE ROLE OF MTNC OXIDE IN CARDIOVASCULAR DEVELOPMENT AND DISEASE: INSIGHTS GAiNED FROM GENETICALLY ENGINEERED MOUSE MODELS OF HUMAN DISEASE B y Tony Lee A thesis submitted in conformity with the requirements for the degree of Master's of Science (2000) Instinite of Medical Science, University of Toronto In the first expenmental series, the antiatherosclerotic effects of Enalûpril vrrsus Irbesartan were compared in the LDL-R knockout mouse model.
    [Show full text]
  • Hair Growth Stimulation with Nitroxide and Other Radicals
    Europaisches Patentamt 263 European Patent Office © Publication number: 0 327 Office europeen des brevets A1 © EUROPEAN PATENT APPLICATION © Application number: 89300785.6 © Int. CI.4: A61 K 7/06 , A61K 47/00 © Date of filing: 27.01.89 © Priority: 29.01.88 US 149720 © Applicant: PROCTOR, Peter H. Twelve Oaks Medical Tower 4125 Southwest © Date of publication of application: Freeway 09.08.89 Bulletin 89/32 Suite 1616 Houston, TX 77027(US) © Designated Contracting States: © Inventor: PROCTOR, Peter H. AT BE CH OE ES FR GB GR IT Li LU NL SE Twelve Oaks Medical Tower 4125 Southwest Freeway Suite 1616 Houston, TX 77027(US) © Representative: Gore, Peter Manson et al W.P. THOMPSON & CO. Coopers Building Church Street Liverpool L1 3AB(GB) © Hair growth stimulation with nitroxide and other radicals. © Hair growth stimulation with nitroxide and other radicals. A nitroxide radical source compound is applied topically with an adjuvant selected from reducing agents, hydroxyl radical scavengers and antioxidants to activate formation of the nitroxide radical and/or to protect the nitroxide radical from reaction with other free radicals. Also disclosed is a kit for preparing a unit dose for topical application of a nitric oxide generating compound and a reducing agent reactive therewith to form nitric oxide on or in the skin. Other adjuvants include SOD and antiandrogens. Various other radical-forming hair growth stimulants and preparations thereof are disclosed. < w CO CM IN CM CO © Q. Ill Xerox Copy Centre EP 0 327 263 A1 rIAIR GROWTH STIMULATION WITH NITROXIDE AND OTHER RADICALS This invention relates to a composition and method for stimulating hair growth, and to a kit for preparation of such a composition.
    [Show full text]
  • Grade 6: the Heart and Circulatory System Lesson 1: the Heart Lesson 2: the Heart Rate Lesson 3: the Circulatory System and Blood
    Grade 6: The Heart and Circulatory System Lesson 1: The Heart Lesson 2: The Heart Rate Lesson 3: The Circulatory System and Blood Objectives: 1. Students will identify the four chambers of the heart 2. Students will identify four important structures of the Circulatory System and what they do. 3. Students will explain heart rate and be able to take their resting and active heart rates. 4. Students will describe the major functions of the Circulatory System. 5. Students will explain the role of the heart in circulation 6. Students will give a basic explanation of the cardio-pulmonary sequence. 7. Students will describe systemic circulation. Materials: Lesson 1: • Animal heart (Example: cow, pig, sheep) • Note cards • Picture of the heart (See Figure 1) • Dissection tools (Scissors, pan, etc.) Lesson 2: • Small drum • Watch or clock with second hand, or time • Optional: Stethoscope Lesson 3: • Corn Syrup • Plastic Beads: flat red disks, white ovals, green or blue seed beads • “Explain” experiment (per group): o Two small balloons or large finger cots o One clear tube (1/2” diameter) about 8” long o One clear tube (3/4” diameter) about 8” long o 16 - 20 oz. water o Red food coloring o Measuring cup o Funnel o Two empty plastic containers (such as cottage cheese or yogurt cartons) Activity Summary: In this lesson students will learn the basic functioning of the heart, Circulatory System and blood, the connection to lung functioning, and the activity of the Grade 6: The Heart & Circulatory System – Revised 2008 Page 1 Circulatory System in the body.
    [Show full text]